Lilly reports mixed data for CGRP mAb in Phase III cluster headache trials

Eli Lilly and Co. (NYSE:LLY) said galcanezumab met the primary endpoint in a Phase III trial to prevent episodic cluster headache but missed in a Phase III trial in chronic cluster headache. Lilly

Read the full 334 word article

User Sign In